Stock DMYD B DIAMYD MEDICAL AB
Add to a list
To use this feature you must be a member
Log inSign up

All News Diamyd Medical AB

Equities

DMYD B

SE0005162880

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:45 2024-05-24 am EDT 		5-day change 1st Jan Change
11.48 SEK -2.38% Intraday chart for Diamyd Medical AB -4.49% +74.73%
May. 16 Diamyd Medical AB Updates on the Registrational Phase 3 Trial CI
Apr. 18 Diamyd Medical Raises SEK57 Million in Rights Issue MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Diamyd Medical updates on the registrational Phase 3 trial; upcoming interim analysis and enrollment
AQ
Diamyd Medical AB Updates on the Registrational Phase 3 Trial
CI
Diamyd Medical Raises SEK57 Million in Rights Issue
MT
Diamyd Medical announces final outcome in the company's rights issue
AQ
Diamyd Medical announces preliminary outcome in the company's rights issue
AQ
Recruitment milestone reached in Diamyd® Phase 3 trial
AQ
Recruitment Milestone Reaches in Diamyd® Phase 3 Trial
CI
Diamyd Medical led ASSET innovation partnership organizes a workshop on the future treatment of Type 1 Diabetes
AQ
Diamyd Medical's main Shareholders announce their subscription commitments in the ongoing rights issue
AQ
Diamyd Medical publishes prospectus with regards to the rights issue
AQ
Quarterly Report II 23/24
AQ
Diamyd Medical AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024
CI
Diamyd Medical to Raise SEK114 Million Via Share Offering
MT
The Board of Directors in Diamyd Medical have resolved on a rights issue of approximately SEK 114 million
AQ
Diamyd Medical to present new genetic data at the ASIT summit in Boston, MA
AQ
Diamyd Medical to Present New Genetic Data at the ASIT Summit in Boston, MA
CI
Diamyd Medical Secures US FDA Fast Track Designation for Type 1 Diabetes Treatment
MT
Diamyd Medical receives U.S. FDA Fast Track designation for Diamyd®
AQ
Publication in Diabetologia highlights AI's potential for Type 1 Diabetes screening
AQ
In-depth analysis of Diamyd® Phase II trial further supports value of preserved insulin secretion
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DMYD B Stock
  4. News Diamyd Medical AB